Trastuzumab-Deruxtecan (T-DXd) Clinical Trials (2026): 3 Studies for Breast Cancer & Colon Cancer Adenocarcinoma
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
3 Trastuzumab-Deruxtecan (T-DXd) clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 2 indications (including Breast Cancer & Colon Cancer Adenocarcinoma) and 250 total planned enrollment. 1 Phase 3 Trastuzumab-Deruxtecan (T-DXd) trial and 2 Phase 2 are listed. 2 Trastuzumab-Deruxtecan (T-DXd) clinical trials are actively recruiting. Most recent activity: NCT06643585 (Apr 2032).
Trastuzumab-Deruxtecan (T-DXd) clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | Total |
|---|---|---|---|
| P2 | 1 | 1 | 2 |
| P3 | 1 | 1 |
Recruiting Trastuzumab-Deruxtecan (T-DXd) clinical trials (2)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT06643585 | SURVIVE HERoesA Randomized Secondary Adjuvant Treatment Intervention Study Comparing Trastuzumab-Deruxtecan to SOC Therapy in eBC Patients With Molecular Relapse | P3 | Breast Cancer | 180 | Apr 2025 |
| NCT07407465 | CHIMERAUpfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer. | P2 | Colorectal Cancer | 42 | Oct 2025 |
Trastuzumab-Deruxtecan (T-DXd) clinical trials by indication
Breast Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06643585 | SURVIVE HERoes | P3 | recruiting | A Randomized Secondary Adjuvant Treatment Intervention Study Comparing Trastuzumab-Deruxtecan to SOC Therapy in eBC Patients With Molecular Relapse |
| NCT06048718 | TUXEDO-4 | P2 | active not recruiting | T-DXd Therapy for HER2-low Breast Cancer Patients With Brain Metastases |
Colorectal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07407465 | CHIMERA | P2 | recruiting | Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer. |
Trastuzumab-Deruxtecan (T-DXd) pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| SURVIVE HERoes | NCT06643585 | P3 | recruiting | Breast Cancer | 180 | — |
| CHIMERA | NCT07407465 | P2 | recruiting | Colorectal Cancer | 42 | — |
| TUXEDO-4 | NCT06048718 | P2 | active not recruiting | Breast Cancer | 28 | PMID 40018758 |
All Trastuzumab-Deruxtecan (T-DXd) trials (3)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT06643585 | SURVIVE HERoes | A Randomized Secondary Adjuvant Treatment Intervention Study Comparing Trastuzumab-Deruxtecan to SOC Therapy in eBC Patients With Molecular Relapse | P3 | recruiting | 180 | Prof. Wolfgang Janni | Apr 2025 |
| NCT07407465 | CHIMERA | Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer. | P2 | recruiting | 42 | Gruppo Oncologico del Nord-Ovest | Oct 2025 |
| NCT06048718 | TUXEDO-4 | T-DXd Therapy for HER2-low Breast Cancer Patients With Brain Metastases | P2 | active not recruiting | 28 | MedSIR | Jun 2024 |
Trastuzumab-Deruxtecan (T-DXd) clinical trials: frequently asked questions
- How many Trastuzumab-Deruxtecan (T-DXd) clinical trials are there?
- 3 Trastuzumab-Deruxtecan (T-DXd) clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 2 are actively recruiting participants.
- Are Trastuzumab-Deruxtecan (T-DXd) clinical trials recruiting in 2026?
- Yes — 2 Trastuzumab-Deruxtecan (T-DXd) trials are actively recruiting in 2026. See the recruiting trials and the per-state site list further down this page.
- What conditions is Trastuzumab-Deruxtecan (T-DXd) being studied for?
- Trastuzumab-Deruxtecan (T-DXd) is being studied for Breast Cancer, Colon Cancer Adenocarcinoma, Colon Cancer Metastatic, Colorectal Adenocarcinoma, Colorectal Cancer and 4 more. The trials are grouped by indication on this page.
- What phase is Trastuzumab-Deruxtecan (T-DXd) in?
- Trastuzumab-Deruxtecan (T-DXd) clinical trials span 1 Phase 3, 2 Phase 2. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Trastuzumab-Deruxtecan (T-DXd) clinical trials?
- The lead sponsor across the most Trastuzumab-Deruxtecan (T-DXd) trials is Gruppo Oncologico del Nord-Ovest, with 2 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Trastuzumab-Deruxtecan (T-DXd)as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: